Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
A patient received a dose of Arexvy after a temperature excursion; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a 87-year-old female patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced incorrect storage of drug (Verbatim: A patient received a dose of Arexvy after a temperature excursion). The outcome of the incorrect storage of drug was not applicable. Additional Information: GSK Receipt Date: 18-JUN-2025 The pharmacist called to request information about the stability of Arexvy vaccines exposed to 70 deg F for 2 hours. No prior excursion reported. The healthcare professional wanted to know the stability information. The healthcare professional would like to know the recommendations after vaccinating patient with Arexvy after this temperature excursion which led to incorrect storage of drug. The second patient who received the dose of Arexvy after a temperature excursion was an 87 year old female.; Sender's Comments: US-GSK-US2025076610:same reporter